New drug cocktail aims to tame deadly immune storm in lymphoma
NCT ID NCT07270835
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This study tests a combination of two drugs, zanubrutinib and rituximab, for people with B-cell lymphoma who develop a severe immune overreaction called hemophagocytic lymphohistiocytosis (HLH). The trial will enroll 40 participants and aims to see how well the treatment controls HLH after 4 weeks. The approach adds targeted therapy to standard care, potentially offering a new way to manage this dangerous complication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib and rituximab
What this could lead to
If successful, this combination could offer a new treatment option for a rare and life-threatening complication of B-cell lymphoma.
What could go wrong
This is a small, early-phase trial with only 40 participants. The treatment may not work for everyone, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.